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Abstract Brain tumors, benign or malignant, are char-
acterized by a very high degree of vascularization. Recent
accumulating evidence suggests that during development
the neuronal wiring follows the same routes as the vascu-
lature and that these two systems may share some of the
same factors for guidance. Thus, expression of dual
angiogenic/neurogenic growth factors was evaluated by
in situ hybridization in human primary brain tumors of
three different types, i.e., astrocytomas, oligodendroglio-
mas, and ependymomas, of increasing grades, in relation
with the grade and type of the tumor. For this evaluation
we selected vascular endothelial growth factor (VEGF-A)
and its receptors VEGF-R1 and VEGF-R2 and the neuro-
pilins 1 and 2 (NRP-1 and NRP-2), which have proangio-
genic properties, platelet-derived growth factor (PDGF)
receptor-beta (PDGF-Rb), which is required for the func-
tional maturation of blood vessels, the ephrins and their
Eph receptors, angiotensinogen (AGT) and thrombospon-
din-2 (TSP-2), which have potential antiangiogenic prop-
erties, and netrin-1 (Net-1), which regulates vascular
architecture. We show that the expression of the VEGF-
NRP system, PDGF-Rb, TSP-2, AGT, and Net-1 are dif-
ferentially regulated, either increased or decreased, in
relation with the type and grade of the tumor, whereas
regulation of the ephrinB system does not seem to be rel-
evant in these human brain tumors.
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Abbreviations
VEGF Vascular endothelial growth factor
NRP Neuropilin
PDGFRb Platelet-derived growth factor receptor-beta
Eph Ephrin
AGT Angiotensinogen
TSP-2 Thrombospondin-2
Net-1 Netrin-1
Astro Astrocytoma
GBM Glioblastoma multiforme
Oligo Oligodendroglioma
Epend Ependymoma
Introduction
A histological feature common to all brain tumors is a high
density of vascularization, required for the rapid growth of
the tumor. It is generally accepted that cancer recapitulates,
at least in part, developmental programs. Normal vasculature
is hierarchically assembled, while the blood vessels of can-
cers retain the disordered and leaky structure of immature
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developing vasculature. The status of the specialized cere-
bral vasculature, the blood–brain barrier (BBB), is modified
in brain tumors, with increased permeability in high-grade
cancer (grade III and IV tumors).
Extensive similarities have been recognized between the
development of nerves and blood vessels. Branched
structures require guidance cues, and it has been shown that
during development these systems share the same molec-
ular cues [1–3]. The build-up of a vascular system requires
precise control of the growth and branching of new vessels.
The genetic control of families of molecules, in particular
of peptides and their cognate receptors, is responsible for
attractive and repulsive cues. Some of these peptide path-
ways have also been previously involved in controlling
neuronal guidance, modulating physiological as well as
pathological processes. Thus, the overall similarity
observed between the vascular tree and the nervous system
has led to the concept of two integrated systems, possibly
using the molecular control of the same factors. These
neural/vascular families of peptides have been evaluated in
detail in vascular development, however they have
received less attention, with the exception of the vascular
endothelial growth factor (VEGF) system, in postdevel-
opmental stage of angiogenesis in humans, in particular in
angiogenic neovessels associated to human primary cancers
of the central nervous system [4]. Therefore, cross-reactivity
between growth factors regulating the development of the
central nervous system (CNS) and angiogenesis, including
tumoral angiogenesis, and dual functions for these factors,
may be postulated.
We have previously shown that the components of the
renin–angiotensin system may be survival factors for
human brain-derived tumors [5]. On the other hand, in the
nervous system the ephrin and NRP-VEGF systems exert
repulsive action on axonal guidance, the netrins are
involved in neuron migration, and during neural tube
development, netrin-1 antagonizes platelet-derived growth
factor (PDGF) effects. In the present study, the parallelism
between the vascular tree and the neural architecture
together with the concept of factors targeting both blood
vessels and nerves led us to assess using molecular his-
tology the expression of such dual neurogenic/angiogenic
factors in primary human glial and nonglial brain tumors of
different grades. For this evaluation we selected VEGF-A
and its receptors VEGF-R1 and VEGF-R2 as well as
neuropilins 1 and 2 (NRP-1 and NRP-2), which have
proangiogenic properties, platelet-derived growth factor
receptor-beta (PDGF-Rb), which is required for the func-
tional maturation of blood vessels, netrin-1 (Net-1), which
regulates vascular architecture, and the ephrinBs and their
Eph receptors, angiotensinogen (AGT) and thrombospon-
din-2 (TSP-2), which have potential antiangiogenic prop-
erties. Our aims are to decipher putative cooperation
between these dual vascular/neural growth factors and to
evaluate new potential markers which can be associated
with brain cancer progression and may be targets for
therapeutic intervention.
Materials and methods
Ex vivo collection and classification of the human
surgical specimens
Human brain cancer specimens (n = 6/cancer type and
grade) were retrospectively selected from the tissue bank of
the University Institute of Pathology, according to type and
grade as the selection criteria, after full diagnostic proce-
dure had been performed. The protocol was approved by
the Ethics Committee of the University Hospital (CHUV)
in Lausanne. A histological hematoxylin–eosin-stained
slide of the selected sample, or of the selected fragment if
several tumor fragments were available, was examined by
an experienced neuropathologist to control the tumoral
characteristics (type and grade) of the sample, before
in situ hybridization was performed. Tumors of the central
nervous system were classified by the World Health
Organization (WHO) classification system according to a
‘‘malignancy scale’’ depending on defined criteria. Grade I
lesions include tumors with low proliferative potential and
the possibility of cure following surgical resection only.
Grade II lesions are infiltrative in nature and recur despite
low proliferative activity, and may progress to higher grade
of malignancy. Grade III lesions are tumors with histo-
logical evidence of malignancy, including nuclear atypia
and high proliferative activity. Grade IV lesions are cyto-
logically malignant, very highly proliferative, angiogenic
and infiltrative, necrotic tumors. The WHO classification
system was followed for evaluation of the selected tumors
of this project. Tissues were fixed in buffered paraformal-
dehyde and embedded in paraffin. Paraffin-embedded tis-
sues were cut at 5 lm and deparaffinized in graded
alcohols. Samples were then exposed to probes of the
factors under evaluation.
Molecular histology
Sense and antisense probes were generated from all com-
plementary DNAs (cDNAs) as control for specificity of
labeling and as specific labeling probe, respectively. In situ
hybridization was performed using the sense and antisense
probes, according to the technique previously described in
detail [6] with minor modifications. Briefly, complemen-
tary RNA (cRNA) probes were labeled by in vitro tran-
scription in the presence of 35S-UTP. The radioactive
labeled riboprobes were dissolved in a hybridization
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mixture, and deposited on the sections. The hybridization
(16 h at 50C) was followed by a series of washings at
various stringencies and temperatures and one step of
RNAse treatment to cleave off the single strands of the
unhybridized riboprobes. Macroscopic semiquantitative
evaluation of the hybridization signal was carried out by
apposition of the slides on an X-ray film (Kodak XMR)
which was photographically processed after 48 h. This
macroscopic picture on the film revealed an overview of
the tissue distribution of the labeling with a view of the
whole section at once. A microscopic image was obtained
on the same slides as the macroscopic pictures after dip-
ping in liquid photographic emulsion (NTB2 Kodak). The
microscopic pictures were obtained after photographic
development and counterstaining with toluidine blue.
These slides were used to evaluate the distribution of the
labeled cells and to compare the intensity of the hybrid-
ization signals between the different cancers at increasing
stages of tumor progression. The following cDNAs were
used to generate cRNA labeled probes: PDGF-Rb
(920 bp); VEGF-A (576 bp); VEGF-R1 (1,610 bp) and
VEGF-R2 (1,350 bp); NRP-1 (1,929 bp) and NRP-2
(2,102 bp); EphrinB1 (941 bp) and Ephrin B2 (1,069 bp);
EPHB4 (972 bp); Net-1 (1,900 bp); AGT (1,000 bp); TSP-
2 (1,380 bp). In parallel and in the same series of slides,
control of labeling specificity was carried out using the
sense probes. No specific localization was observed; only a
weak and uniform low-level background could be detected
(results not shown).
Evaluation of hybridized slides
The hybridized samples were quoted by three scientists
(M.C., J.-M.G., and L.J.-J.), and quotations further vali-
dated independently by two pathologists (R.C.J. and B.L.).
Each hybridized slide was graded following a scale
between 0 (no labeling detectable) and 4 (maximum
intensity of labeling). All slides of one tumor type were
hybridized at the same time and with the same batch of
riboprobe. In each group the individual scores of all tissue
samples were averaged to obtain mean values. Since for
each marker all tumors of all grades were hybridized at the
same time and with the same probe batch, comparison
between these samples is acceptable. These values were
compared with each other within a group of sections
hybridized with the same batch of radiolabeled probe.
Results
The expression of several markers was heterogeneous
between tumors of the same grade. In the figures we
present a consensus analysis of representative pictures.
Therefore, in this manuscript ‘‘representative’’ means that
the tumor tissue examined displayed the histological
characteristics of the type of cancer and the grade defined,
and corresponded to the majority of the messenger RNA
(mRNA) expression analyzed. However, there may be
minor areas of a specific sample, with all the requested
histological characteristics, which may have a different
pattern of expression. Following this evaluation process,
representative pictures of the observations of primary
human astroglial (Fig. 1), oligodendroglial (not shown),
and ependymomal (Fig. 2) tumors allowed determination
of the cells expressing the mRNAs for the selected factors.
The semiquantitative mRNA expression levels are reported
for tumoral tissue (Table 1) and its associated vasculature
(Table 2).
Astroglial tumors (Fig. 1) In low-grade (grade I–III)
astrocytomas, VEGF-A expression was detected in a few
large cells (Fig. 1, arrow) of the tumor. In high-grade tumors
[grade IV astrocytomas/glioblastoma (GBM)] VEGF-A
expression was highly increased in the tumor. The expres-
sion of VEGF-R1 increased with tumor grade in the tumor
vasculature, in particular in the glomeruloid structures of
GBM (Fig. 1, arrow). VEGF-R2 (not shown) expression was
found in a few vascular and perivascular cells localized in
tumors of all grades, not obviously associated with grade.
NRP-1 was highly expressed by a few localized large cells in
low-grade tumors, and highly expressed in some highly
vascularized abnormal structures of GBM. NRP-2 expres-
sion was associated with large cells, which we identified as
reactive astrocytes, in low-grade cancer, and decreased with
tumor grade. PDGF-Rb expression was detected in scattered
perivascular cells in low-grade astrocytomas and in the
glomeruloid vessels of GBM (Fig. 1, arrow), but not in all
vessels of high-grade astrocytomas. Net-1 expression (not
shown) was analyzed only in low-grade astrocytoma, and
was found at high level in reactive astrocytes. EphrinB1 (not
shown) was expressed at low level in only a few perivascular
cells in all grades of astrocytoma without obvious relation-
ship with grade. EphrinB2 (not shown) had the highest
expression of all EphB mRNAs evaluated and was mainly
observed in the tumor vasculature, possibly endothelial cells,
with no obvious relationship with tumor grade. EPHB4 (not
shown) expression was very low in all grades of astrocytoma.
In agreement with the our previous results [5], AGT
expression (not shown) was mainly localized in large cells,
decreasing with the increase of tumor grade. The level of
TSP-2 expression did not markedly change with grade, but
the typeof cells expressing itwas modified. TSP-2 was expressed
by large perivascular cells in low-grade tumors (Fig. 1, arrow),
and by smaller cells in high-grade astrocytomas.
Oligodendroglial tumors (not shown) VEGF-A was not,
or only at very low level, expressed in low-grade (grade II)
oligodendrogliomas, but dramatically increased in high-
J Neurooncol (2012) 107:29–36 31
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grade (grade III) tumors, whereas VEGF-R1 was already
expressed in low-grade oligodendrogliomas, also increasing
with grade. VEGF-R2 was not detected in low-grade oligo-
dendrogliomas and was not evaluated in high-grade tumors.
NRP-1 was expressed at higher level in nontumoral tissue
surrounding the tumor than by the tumor tissue itself.
Expression was high in large cells and in perivascular cells of
low-grade tumors, and labeling decreased with increasing
tumor grade. NRP-2 was almost not expressed in all grades of
cancer. In low-grade oligodendrogliomas, PDGF-Rb
expression was observed in low- and high-grade oligoden-
drogliomas, in most tumor-associated vessels and in reactive
astrocytes. Net-1 evaluation was performed only in high-
grade tumors and was detected in only few scattered cells.
EphrinB1, EphrinB2, and EPHB4 expression was detected in
large cells of localized areas, possibly reactive astrocytes or
neurons, in low-grade oligodendrogliomas, and in isolated
Fig. 1 Cell distribution determined by in situ hybridization of the
mRNAs for neurogenic/angiogenic factors in grade I/II astrocytoma
and grade IV/glioblastoma. Representative histological pictures of
in situ hybridization slides of human low-grade astrocytomas (left)
and high-grade astrocytoma (glioblastoma/GBM) (right) processed
for in situ hybridization with the corresponding antisense cRNAs
probes. Bar 50 lm. Arrows areas of positive labeling. Initial
magnification 940
Fig. 2 Cell distribution determined by in situ hybridization of the
mRNAs for neurogenic/angiogenic factors in grade II ependymoma
and grade III ependymoma. Histological pictures of in situ hybrid-
ization slides of human low-grade (grade II) (left) and high-grade
(grade III) (right) ependymomas processed for in situ hybridization
with the corresponding antisense cRNAs probes. Bar 50 lm. Arrows
areas of positive labeling. Initial magnification 940
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smaller cells of high-grade tumors, EphrinB2 being pre-
dominantly expressed compared with EphrinB1 and EPHB4.
AGT was diffusely detected in localized cells in tumors of
both grades, possibly at higher level in low-grade oligo-
dendrogliomas. TSP-2 evaluation was not performed for
oligodendrogliomas.
Ependymomal tumors (Fig. 2) VEGF-A expression was
observed in scattered tumor cells of low-grade (grade II)
ependymomas (Fig. 2, arrow) and at much higher levels in
tumor cells surrounding tumor-associated vessels of high-
grade (grade III) ependymomas, as well as the vascular
cells themselves (not shown). VEGF-R1 expression was
localized in the tumor vessels, and expression levels
increased from low grade to high grade, associated to an
increased number of vessels. The expression of VEGF-R2
(Fig. 2, arrow) was lower than that of VEGF-R1, increas-
ing with tumor grade. The expression of NRP-1 in the
tumor tissue of low-grade tumors (Fig. 2, arrow) was
associated with the tumor cells rather than with the tumor
vessels. NRP-1 expression increased with grade in the
tumor vessels. NRP-2 (not shown) was expressed at very
low level only by very few cells in both grades of tumor. In
low-grade ependymomas, PDGF-Rb expression was
observed in most tumor-associated vessels, but only in very
few vascular cells of the typical ‘‘hen-feet’’ tumor vessels
(Fig. 2, arrow) of high-grade ependymomas. Net-1 (not
shown) was largely expressed by tumor cells without any
obvious changes with tumor grade. In low-grade ependy-
momas, EphrinB1 and EPHB4 (not shown) were generally
diffusely expressed at low level. EphrinB2 was expressed
by the tumor vasculature in both grades of tumor. AGT (not
shown) was diffusely expressed in both grades of epen-
dymoma, without obvious relationship with grade. In low-
grade ependymomas, TSP-2 expression (Fig. 2, arrow) was
observed in few isolated tumor cells and in more cells,
vascular and tumor cells, of high-grade ependymomas.
Table 1 Semiquantitative evaluation of mRNA expression levels determined by in situ hybridization in the tumor tissue
astro I ? II astro III GBM oligo II oligo III epend II epend III
VEGF-A ? ? ??? (?) ??? ? ???
VEGFR1 (?) - (?) - - ? ?
VEGF R2 - (?) - - n.d. - -
NRP-1 ? ? ?? ? ? ? ??
NRP-2 ? ? (?) - - - (?)
PDGF-Rb - - - (?) (?) (?) -
Net-1 ??? (?) ? n.d. (?) ? ?
EphrinB1 (?) ? ? (?) ? (?) –
EphrinB2 (?) ? - (?) ? (?) -
EPHB4 - ? - (?) ? ? (?)
AGT ? ?? ? ? ? ?? ?
TSP-2 ?? ? ? n.d. n.d. (?) ???
- No expression; (?), ?, ??, ??? very low, low, medium and very high expression; n.d. not determined
Table 2 Semiquantitative evaluation of mRNA expression levels determined by in situ hybridization in the tumor-associated vasculature
astro I?II astro III GBM oligo II oligo III epend II epend III
VEGF-A ? - - - - ?? ???
VEGF R1 ? ? ??? (?) ? ?? ???
VEGF R2 (?) (?) (?) (?) n.d. ? ??
NRP-1 ? ? ?? - (?) ? ??
NRP-2 (?) ? (?) - - - -
PDGF-Rb ?? ?? ? ? ? ?? ?
Net-1 ?? - - n.d. - - (?)
EphrinB1 (?) (?) (?) - - - -
EphrinB2 ? (?) ? (?) ? - ?
EPHB4 (?) (?) - - (?) - (?)
AGT ? ? - - ? - -
TSP-2 ? ? ? n.d. n.d. ? ?
- No expression; (?), ?, ??, ??? very low, low, medium, and very high expression; n.d. not determined
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Thus, in the tumor tissue (Table 1), VEGF-A expression
increased with grade, in all tumor types. However, both
VEGF-R1 and VEGF-R2 were only marginally expressed.
NRP-1 was expressed at low levels in low-grade tumors of
the three types, and increased with tumor grade in astro-
cytomas. In the other cancers, NRP-2 was only marginally
expressed, and its expression was not grade related. No
PDGF-Rb expression was detected in the tumor tissue of
all tumor types and grades. All components of the ephrinB
system evaluated were only sporadically expressed, and no
obvious changes of expression with grade were apparent in
the tumor tissue. Confirming our previous results in
astrocytomas only [5], AGT expression decreased with
grade in astrocytoma and ependymoma, whereas this
relation was less clear in oligodendroglioma. TSP-2 and
Net-1 expression decreased with grade in astrocytomas,
whereas TSP-2 expression, but not Net-1 expression,
increased with tumor grade in ependymomas.
In tumor-associated vasculature (Table 2), VEGF-A was
not expressed in tumor vessels in astrocytomas and oligo-
dendrogliomas, but was highly expressed in ependymomas,
increasing with tumor grade, suggesting an autocrine
effect. VEGF-R1 and NRP-1 expression in tumor vessels
increased with grade in astrocytomas and ependymomas,
whereas VEGF-R2 expression increased with grade in
ependymomas, but not in the other two types of cancers.
NRP-2 was only marginally detected in all cancers of any
grade. PDGF-Rb expression decreased with increasing
tumor grade in astrocytomas and ependymomas. Net-1
expression was clearly observed only in low-grade astro-
cytoma vessels. All components of the ephrinB system
evaluated were only marginally expressed in tumor-asso-
ciated vessels, and no obvious changes of expression with
grade were apparent. AGT was generally not expressed in
all tumor-associated vessels, whereas TSP-2 expression in
the tumor vessels was low and not grade related in astro-
cytomas, while it increased with grade in ependymomas.
Discussion
Brain tumors are highly vascularized, and the cancer-
associated vasculature recapitulates in part the properties of
the developmental vascularization, displaying branching
structures, high permeability, and high proliferative rates.
The development of the vertebrate vascular system requires
precise control of the growth and branching of new vessels
mediated by families of peptides and their receptors
(reviewed in 1). Some of these peptide pathways have also
been involved in controlling neuronal guidance. During
developmental vascularization the VEGF/VEGFR/NRP
system is involved in the early steps of angiogenesis,
whereas the ephrin system, in particular EPHB4/ephrinB2,
controls branching, maturation, and the arteriovenous
asymmetry of the vasculature in later stages [7–10], while in
the nervous system, the ephrin system exerts repulsive
action. The VEGF-A and its receptors VEGF-R1 and
VEGF-R2 are the major system shaping vasculogenesis and
angiogenesis during development. NRP-1 and NRP-2
receptors can bind VEGF, forming complexes with either
VEGF-R1 or VEGF-R2. NRP-1 and NRP-2 are membrane-
bound receptors with two different ligands, the semaphorins
(repulsive for axonal guidance) and the VEGFs (attractive
for angiogenesis). The netrins are a group of angiogenic
factors also involved in neuron migration, whose role in
angiogenesis is ambiguous as it induces context-dependent
responses, either pro- or antiangiogenic or attractive or
repulsive effects (reviewed in 1, 2). The cooperation of
PDGF and its PDGF-Rb receptor is required to attract
pericytes and form and stabilize fully differentiated vessels
[11]. During development of the neural tube, netrin-1
antagonizes the chemoattraction of PDGF and thus prevents
the effects of PDGF on the normal dispersion of precursor
cells [12]. It has been previously shown in experimental
models that Net-1 binding to its UNC5B receptor induces
endothelial repulsion and inhibits sprouting angiogenesis
[13]. The absence of the ligand Net-1 on its receptors has
been shown to result in the activation of cell death by
apoptosis [14]. However, these results contradict previous
information which suggests that the netrins stimulate pro-
liferation, migration, and tube formation of human endo-
thelial cells in a UNC5B-independent manner [15].
To control vascular development, the proangiogenic
pathways can be antagonized by the antiangiogenic sys-
tems. AGT, and TSP-1 and TSP-2 have been previously
suggested to play antiangiogenic roles. AGT, the major
source of angiotensin II, not only controls vascular wall
resistance but also angiogenesis. AGT is abundantly
expressed in some areas of the brain, and its antiangiogenic
properties have been recently demonstrated in a mouse
model overexpressing AGT [16]. TSP-1 and TSP-2 are
powerful antiangiogenic factors, counterbalancing the
effects of VEGF and, at least in humans, may participate in
the blockade of the remodeling of a functional vascular
architecture. TSP-1 and TSP-2 appear to mediate their anti-
antiangiogenic effects by inhibiting neoangiogenesis and
endothelial cell proliferation and migration.
In cancer, VEGF-A produced by the tumor stimulates
permeabilization of preexisting capillaries and proliferation
of endothelial cells through paracrine activation of one of
its receptors on tumor vessels, to form neovessels with
distorted structures. As expected from previous informa-
tion, the expression of VEGF-A mRNA increased strongly
with tumor progression in the tumoral tissue, localized in
clusters of tumor cells at the invasion front of the tumor.
Surprisingly, the expression of not only VEGF-A but also
34 J Neurooncol (2012) 107:29–36
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its VEGF-R1 receptor by the tumor vessels increased in
grade III ependymoma, suggesting an autocrine loop. In
the brain cancers that we analyzed, NRP-1 and NRP-2
displayed a constant low level of expression, mainly
detected in endothelial cells and in reactive perivascular
cells in infiltrative areas of the tumor. It has been previ-
ously shown that NRP1 is mainly expressed by carcinomas
and NRP2 mainly by neuronal tumors, glioblastomas, and
melanomas [17]. In our series of human brain tumors,
expression of PDGF-Rb did not increase concomitantly
with the large increase of VEGF-A expression in stromal
cells and VEGF-R1 in the vessel wall as tumor grade
increased. Thus, we can hypothesize that, in human brain
cancer, when stimulated by VEGF-A, new vessels form,
but fail to organize functional vessels in the absence of
PDGF-Rb. The comparison between VEGF-R1 and VEGF-
R2 expression suggested that VEGF-R1 mRNA increased
in the vessels with tumor progression, while VEGF-R2
decreased. Presently, we have no explanation for this
observation.
The ephrin systems have been generally associated with
cancer, in cancer cells and stroma, but can be downregu-
lated at advanced stages, receptors and ligands being dis-
cordantly regulated [18]. In the primary human brain
cancers that we studied, the expression of the components
of the ephrinB system evaluated did not display a clear
relationship with either grade or cancer type, EphrinB2
being the most highly expressed, but anyhow at low level
and possibly only in the remaining nontumoral neural cells,
reactive astrocytes or remaining neurons, of the cancer
tissue. EPHB4 and EphrinB2 are necessary for vascular
development, and for tumor angiogenesis, cross-talking
with the VEGF system [1, 3, 19], however the role of
EphrinB2 and EPHB4 in cancer cells is complex, para-
doxical, and sometimes opposite. It has been shown that
EPHB4 on tumor cells interact with EphrinB2 on endo-
thelial cells, promoting angiogenesis, while EPHB4 may be
important for tumor cell growth, either increasing or
decreasing tumor growth depending on the context; for
example, human colorectal cancers lose expression of
EphB at the adenoma–carcinoma transition, correlated with
cancer progression [20].
We show a clear decrease with tumor grade of Net-1 in
the tumor tissue of astrocytomas. Net-1 was shown to be
upregulated in aggressive neuroblastoma, and has been
associated with poor prognosis in several other aggressive
human cancers. By immunohistochemistry, Net-1 has been
previously demonstrated in tumor cells, but not in the
tumor stroma, confirming our present results. In experi-
mental models of breast cancer, Net-1 binding to its
receptor(s) induced migration, proliferation, and differen-
tiation, while in colorectal cancer, loss of function of the
receptors was prevalent over gain of Net-1 [21, 22].
Generally we observed a decrease of AGT expression
with increasing grade of all three cancer types, confirming
our previous results in astrocytomas [5]. The decrease in
AGT expression corresponds to a loss of AGT antiangio-
genic effects as the tumors progress. The downregulation
of TSP-1 has already been documented [23], and we did
not include it in our study. In our series of human primary
tumors of the brain, we found that, whereas TSP-2
expression did not markedly change with tumor grade, the
type of cells expressing it did change. In low-grade tumors,
remaining neurons or reactive astrocytes expressed it,
while it was expressed by small cells in higher-grade
tumors. Using immunohistochemistry, TSP-1 and TSP-2
protein expression was previously shown to be higher in
glioblastoma than in lower-grade astrocytoma, predomi-
nantly localized in vascular cells, with minimal expression
in the tumor tissue [24–27]. Our results did not confirm the
previously published information that TSP-2, but not TSP-
1, mRNA was correlated with high grade in astrocytomas
[28]. This is an important consideration when evaluating
potential therapeutic targets and may explain discrepancies
between series of samples.
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